Ann: Phase I Clinical Trial Dosing Update No 3, page-39

  1. 863 Posts.
    lightbulb Created with Sketch. 425
    While I share your hopes, there are still plenty of things to worry about with Nyrada.

    1. If AGN's ARG-002 shows promise in their upcoming P2 results, it might negate any need for NYR's asset. If primary brain injury is reduced, secondary injury is naturally reduced as well.
    2. Millions of $0.075 NOX shares are now free on the market... Must be tempting to flip them now for a quick 100%.
    3. No US patent has been granted... The IP is not locked in.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
22.0¢
Change
-0.025(10.2%)
Mkt cap ! $46.40M
Open High Low Value Volume
24.5¢ 25.0¢ 22.0¢ $256.0K 1.085M

Buyers (Bids)

No. Vol. Price($)
3 67420 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 25083 2
View Market Depth
Last trade - 16.10pm 24/06/2025 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.